Welcome to our dedicated page for Jade Biosciences news (Ticker: JBIO), a resource for investors and traders seeking the latest updates and insights on Jade Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jade Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jade Biosciences's position in the market.
Jade Biosciences (Nasdaq: JBIO) reported Q3 2025 results and a corporate update on Nov 13, 2025 highlighting clinical advances and financing.
Key points: presented favorable preclinical safety and translational biomarker data for JADE101 at ASN Kidney Week; initiated a Phase 1 healthy volunteer study with interim biomarker-rich data expected in H1 2026; unveiled JADE201, an afucosylated anti-BAFF-R candidate with first-in-human RA trial planned in H1 2026; completed a $135 million private placement and reported pro forma cash of approximately $325.6 million, funding operations into the first half of 2028.
Jade Biosciences (Nasdaq: JBIO) presented two posters at ASN Kidney Week 2025 on JADE101, an investigational anti-APRIL monoclonal antibody for IgA nephropathy (IgAN).
Key highlights: preclinical NHP safety showed a NOAEL at highest GLP dose, no off-target binding across >6,000 human proteins, no tissue cross-reactivity, and preserved vaccine responses. JADE101 produced reversible IgA reductions ~55–68% and IgM reductions ~62–75% (IgG reductions ~35–48%).
A Phase 1 healthy volunteer trial is ongoing with interim biomarker data expected in first half of 2026; translational analyses reported strong correlations between healthy volunteer and patient biomarker responses (r values up to 0.96) supporting dose selection.
Jade Biosciences (Nasdaq: JBIO) will participate in multiple investor conferences in November 2025, including Wedbush Rewind ASN, Stifel Healthcare, TD Cowen Immunology & Inflammation Virtual Summit, and Jefferies Global Healthcare in London.
Scheduled events include a Wedbush fireside chat on Nov 10, 2025 at 12:40 p.m. ET, a Stifel presentation on Nov 12, 2025 at 4:00 p.m. ET, a TD Cowen presentation on Nov 13, 2025 at 3:00 p.m. ET, and a Jefferies presentation on Nov 17, 2025 at 3:30 p.m. GMT. Live webcasts and archived replays will be available on Jade Biosciences' Events & Presentations page for 90 days after each event.
Jade Biosciences (Nasdaq: JBIO) will present new preclinical safety and translational data for JADE101 at ASN Kidney Week 2025 in Houston, Nov 5–9, 2025. JADE101 is an anti-APRIL monoclonal antibody in development for immunoglobulin A nephropathy (IgAN) and is engineered for subcutaneous dosing based on differentiated preclinical PK/PD in non-human primates.
The company is conducting a Phase 1 healthy volunteer trial of JADE101, with interim data expected in the first half of 2026. Two poster presentations are scheduled on Nov 8, 2025, 10:00 AM–12:00 PM CT: SA-PO0255 (nonclinical safety) and SA-PO0272 (translational framework), presented by Ashley McCord and Brandon Gufford.
Jade Biosciences (Nasdaq: JBIO) announced JADE201, an investigational half-life extended, afucosylated monoclonal antibody targeting BAFF receptor for autoimmune diseases.
Preclinical non-human primate data showed dose-dependent BAFF-R occupancy, sustained B‑cell depletion after a single subcutaneous dose, and ~2x half-life versus ianalumab. JADE201 combines afucosylation for enhanced ADCC and an Fc mutation to extend systemic exposure while preserving activity.
A randomized, placebo-controlled, single-ascending-dose first-in-human trial in rheumatoid arthritis is expected to begin in H1 2026. The company will host a conference call and webcast on Oct 7, 2025 at 8:00 a.m. ET.
Jade Biosciences (Nasdaq: JBIO) announced a private placement expected to raise approximately $135 million in gross proceeds via a PIPE financing, subject to customary closing conditions with an expected close on or about October 8, 2025. The transaction sells 13,368,164 shares at $9.14 and 1,402,092 pre-funded warrants at $9.1399 each (exercise price $0.0001).
After issuance, there will be about 67.4 million shares and equivalents outstanding. The company said net proceeds plus existing cash are expected to fund operations into 1H 2028. Placement agents and a registration rights agreement were disclosed.
Jade Biosciences (NASDAQ:JBIO) has initiated dosing in its Phase 1 clinical trial of JADE101, a novel anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN). The trial marks a significant milestone in developing a potential best-in-class treatment for this autoimmune kidney disease.
The Phase 1 study is designed as a randomized, double-blind, placebo-controlled trial evaluating single ascending subcutaneous doses in healthy volunteers. The company expects to report interim data in H1 2026, which will help determine optimal dosing strategies for future IgAN patient studies.
JADE101 has demonstrated promising preclinical results, including femtomolar binding affinity to APRIL and sustained IgA reductions in non-human primates, suggesting potential for convenient eight-week or longer dosing intervals.
Jade Biosciences (Nasdaq: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in three upcoming healthcare conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (September 3-5), the Stifel Virtual Immunology and Inflammation Forum (September 15-16), and the 11th Annual World Medical Innovation Forum (September 15-17). Management will conduct fireside chats and participate in a panel discussion on immunology, while also hosting one-on-one investor meetings.
Webcasts of the Cantor and Stifel fireside chats will be available on Jade's website with 90-day replay access.
Jade Biosciences (NASDAQ:JBIO) reported Q2 2025 financial results and corporate updates, highlighting progress in its autoimmune disease therapy development. The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrated promising preclinical results with ultra-high binding affinity and sustained IgA suppression. A Phase 1 trial is expected to begin in Q3 2025.
Financial highlights include $220.9 million in cash and equivalents, providing runway through 2027. Q2 2025 saw R&D expenses of $22.5 million and G&A expenses of $5.2 million, with a net loss of $32.1 million. The company also appointed Brad Dahms as CFO and continues development of JADE201, targeting multiple systemic autoimmune diseases, with clinical entry planned for H1 2026.
Jade Biosciences (Nasdaq: JBIO), a biotechnology company developing therapies for autoimmune diseases, has announced its participation in two upcoming investor conferences.
CEO Tom Frohlich and CSO Dr. Andrew King will present at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 p.m. ET, and the 2025 Stifel Biotech Summer Summit on August 13, 2025, at 7:30 a.m. ET. The management team will also host one-on-one investor meetings during both events.
FAQ
What is the current stock price of Jade Biosciences (JBIO)?
What is the market cap of Jade Biosciences (JBIO)?
